SGLT-2 Inhibitor: Difference between revisions
(→Common) |
|||
| (5 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
==Administration== | ==Administration== | ||
*Type: [[Diabetes medication]] | *Type: Oral [[Diabetes medication]] | ||
*Canagliflozin (Invokana), Dapagliflozin (Farxiga), | *Canagliflozin (Invokana), Dapagliflozin (Farxiga), Empagliflozin (Jardiance) are FDA approved for use in type 2 diabetes | ||
==Contraindications== | ==Contraindications== | ||
| Line 8: | Line 8: | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*Euglycemic DKA<ref>[https://www.fda.gov/Drugs/DrugSafety/ucm446845.htm FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood]</ref> | *Euglycemic [[DKA]]<ref>[https://www.fda.gov/Drugs/DrugSafety/ucm446845.htm FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood]</ref> | ||
*Fournier's gangrene (rare) | |||
===Common=== | ===Common=== | ||
*[[UTI]] | *[[UTI]] | ||
*Genital candidiasis | *Genital [[candidiasis]] | ||
*Weight loss | *Weight loss | ||
*Dehydration/Orthostasis | *Dehydration/Orthostasis | ||
| Line 23: | Line 24: | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:Endocrinology]] | |||
Latest revision as of 06:06, 20 August 2022
Administration
- Type: Oral Diabetes medication
- Canagliflozin (Invokana), Dapagliflozin (Farxiga), Empagliflozin (Jardiance) are FDA approved for use in type 2 diabetes
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
- UTI
- Genital candidiasis
- Weight loss
- Dehydration/Orthostasis
Mechanism of Action
- Inhibit sodium-glucose cotransporter 2, decreasing glucose reabsorption in the proximal tubule